Biocon Biologics Limited

Biocon Biologics Limited is a subsidiary of Biocon Limited (BSE: 532523, NSE: BIOCON), an Indian biopharmaceutical company headquartered in Bengaluru. The parent company was founded in 1978, and Biocon Biologics was established as a separate entity in 2020 to focus on biosimilars. As a key subsidiary of a publicly traded company, Biocon Biologics operates as a fully integrated "pure play" biosimilars organization. For the fiscal year ending in March 2025, Biocon Biologics' parent company, Biocon Limited, reported revenues of over ₹16,000 crore (approximately US$1.7 billion).

Biocon Biologics develops, manufactures, and commercializes biosimilars and novel biologics for chronic conditions like diabetes, cancer, and autoimmune diseases. Its product portfolio includes a wide range of biosimilar molecules such as monoclonal antibodies, insulin and insulin analogs, and other recombinant proteins. Key commercialized products include biosimilars for Trastuzumab, Bevacizumab, Insulin Glargine, and Adalimumab, which are marketed in over 120 countries. The company significantly expanded its global commercial footprint by acquiring the biosimilars business of Viatris in 2022.

The company is an active operating company in the biopharmaceutical sector and its patent litigation reflects this posture. The provided data shows Biocon Biologics as a plaintiff in one recent proceeding before the Patent Trial and Appeal Board (PTAB), challenging a patent held by a competitor. This offensive action, aimed at clearing a path for its own products, is typical for a biosimilar manufacturer seeking to enter the market. The company has also been a defendant in patent infringement suits, such as litigation brought by Amgen concerning a denosumab biosimilar.

A notable recent case is the one listed in the provided data: Biocon Biologics, Inc. et al. v. Regeneron Pharmaceuticals, Inc., initiated in April 2026 at the PTAB. This action likely relates to Biocon's development of a biosimilar version of Regeneron's successful drug, Eylea. Historically, Biocon has been involved in several patent disputes related to its biosimilar products, including litigation against Sanofi over an insulin glargine device patent, which it won, clearing a key hurdle for commercialization in the U.S. In 2025, Biocon also settled a patent dispute with Amgen, allowing it to launch its denosumab biosimilars in the U.S.